RxDoctor Payments Data

Shepard Weiner, MD

Cardiovascular Disease · New York, NYNPI 1841234838

Payments from drug & device makers

$167,360in general payments, 2019–2025

Across 151 payments — averaging $1108.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$163K
  • Bayer$4K
  • Boehringer Ingelheim$75
  • Novo Nordisk$73
  • Heartflow, Inc.$70
  • Esperion Therapeutics, Inc.$52
  • plus $98 from 4 others

What the payments were for

  • Consulting fees$17,87811%
  • Speaking & faculty fees$120,46672%
  • Travel & lodging$23,99714%
  • Food & beverage$5,0203%

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$167,360 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$488,961
Medicare patients
745
Services billed
3,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten292$2,360,116
EliquisApixaban279$356,537
XareltoRivaroxaban100$122,238
JardianceEmpagliflozin43$56,157
EntrestoSacubitril/Valsartan22$36,516
OzempicSemaglutide28$34,956
MultaqDronedarone Hcl18$32,829
FarxigaDapagliflozin Propanediol16$23,804
Repatha SureclickEvolocumab20$22,257
BrilintaTicagrelor22$21,359
JanuviaSitagliptin Phosphate15$11,878
Metoprolol Succinate500$10,383
VascepaIcosapent Ethyl17$5,510
Breo ElliptaFluticasone/Vilanterol13$5,316
Incruse ElliptaUmeclidinium Bromide13$4,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$162,742$2,360,116292 claims
Boehringer IngelheimJardiance$75$56,15743 claims
NovartisEntresto$41$36,51622 claims
Novo NordiskOzempic$73$34,95628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →